Novavax (NVAX) – Reuters
-
Novavax says still faces strong headwinds, 2024 sales flat to lower
-
Vaccine maker Novavax tops revenue estimates, eyes more cost cuts
-
US FDA authorizes Novavax's updated COVID shot, shares rise
-
Novavax's updated COVID shot shows immune response against subvariant Eris
-
Novavax forecasts higher-than-expected revenue; shares surge
-
Novavax cut $50 million in costs, plans to slash more, CEO says
-
Novavax's longtime CEO Stanley Erck to retire
-
Novavax cuts full-year revenue forecast again amid weak demand
-
Novavax says Omicron shot shows strong immune response as second booster
-
Novavax tumbles 30% as waning COVID-19 vaccine demand hits outlook
-
Novavax sinks after halving sales forecast on low vaccine demand, supply glut
-
U.S. administers over 7,300 Novavax vaccine doses - CDC
-
EU says Novavax COVID vaccine should carry heart side-effect warning
-
Novavax says U.S. FDA clears COVID vaccine doses for release
-
U.S. CDC recommends Novavax COVID vaccine for adults
-
U.S. FDA authorizes Novavax COVID vaccine for adults
-
Novavax shares jump as FDA panel backs COVID vaccine
-
Novavax says COVID vaccine for U.S. to be manufactured by India's Serum
-
Novavax COVID shot, aimed at vaccine skeptics, overwhelmingly backed by FDA panel
-
U.S. FDA flags risk of heart inflammation after Novavax COVID vaccine
-
Novavax files for authorization of COVID-19 shot among adolescents in Britain
-
Novavax says its COVID vaccine gets India authorisation for teens
-
Novavax COVID vaccine gets interim authorization in Singapore
-
Novavax underdelivers on COVID vaccine promises
-
WHO experts recommend third dose of Novavax COVID vaccine for people with health issues
-
Novavax says it could start making Omicron-specific vaccine in January
-
Novavax completes process for WHO emergency use approval of COVID-19 vaccine
-
Novavax COVID-19 vaccine gets first authorization; expects more within weeks, CEO says
-
Novavax begins early-stage trial for combined influenza/COVID-19 vaccine
-
EU seals deal with Novavax for up to 200 million COVID-19 vaccines
-
AMC jumps more than 18%, other 'meme stocks' mixed
-
Novavax COVID-19 vaccine more than 90% effective in U.S. trial
-
Exclusive: Novavax plans to ship COVID-19 vaccines to Europe from late 2021 - EU source
-
Novavax completes enrolling 30,000 people in U.S. trial of COVID-19 vaccine
-
Wall Street ends higher as tech rally squashes virus fears, but S&P down for week
-
Trump says not pressing U.S. government for coronavirus vaccine for political reasons
-
U.S., European COVID-19 vaccine developers pledge to uphold testing rigour
-
Novavax begins mid-stage study of COVID-19 vaccine in South Africa
-
Vaccine makers including Moderna must hit U.S. timing goals for full payments
-
Novavax to deliver 60 million doses of COVID-19 vaccine candidate to UK
-
Exclusive: U.S. recruits scientists abroad for COVID-19 vaccine trials, pledges access to supply
-
U.S. to pay Pfizer, BioNTech $1.95 billion for COVID-19 vaccine
-
Exclusive: Novavax executives could get big payday even if vaccine fails
-
U.S. signs $450 million contract with Regeneron for COVID-19 therapy
-
Wall Street drops after strong rally as COVID-19 cases mount
-
Emergent signs five-year deal backing J&J COVID-19 vaccine
-
Moderna rally loses steam over COVID-19 vaccine worries
-
S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs
-
S&P 500 futures surge on recovery, vaccine hopes
-
Dollar weakens as investors' risk appetite ramps up
Back to NVAX Stock Lookup
